LONDON, Sept. 9,
2024 /PRNewswire/ -- Virax Biolabs ("Virax" or the
"Company") (NASDAQ: VRAX), an innovative biotechnology company
focused on the detection of immune responses and diagnosis of viral
diseases, today announced that Chief Operating Officer, Dr
Nigel McCracken is presenting at
H.C. Wainwright's 26th Annual Global Investment Conference, held in
New York, NY and that the
pre-recorded and on-demand presentation is now available.
Session details are as follows:
Date: September 9-11, 2024
at Lotte New York Palace Hotel, New York,
NY
Title: Virax BioLabs Company Presentation
Virax Participant: Dr Nigel
McCracken, Chief Operating Officer
Presentation Link: https://ir.viraxbiolabs.com
Virax management will be available during the conference for
one-on-one meetings. Interested parties may request a one-on-one
meeting.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology
company focused on the detection of immune responses to and
diagnosis of viral diseases. Virax Biolabs Group Limited is
currently developing T-Cell-based test technologies with the
intention of providing an immunology profiling platform. T-Cell
testing can be particularly effective in the diagnosis and
therapeutics of post-acute infection syndromes such as Long COVID
and other chronic conditions linked to immune dysregulation.
For more information, please
visit www.viraxbiolabs.com.
Investor Relations Contact:
Russo Partners,
LLC
Nic Johnson and Adanna G. Alexander, Ph.D.
M: 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-presents-at-hc-wainwrights-26th-annual-global-investment-conference-302241974.html
SOURCE Virax Biolabs
